-Erwin Sablon Researcher Activity Profile

Research Author Detailed Information 

Erwin Sablon Publication Rate By Year

Erwin Sablon has published 1 paper(s) in 2006, 6 paper(s) in 2007, for a total of 7 research publications in total.

Erwin E Sablon Author Information

LAST NAME: sablon

FIRST NAME: erwin

INITIALS: E

AFFILIATION:

Papers

Erwin Sablon's Publication Record

1. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Year Published: 2006
Theoretical Biology and Biophysics group, Los Alamos National Laboratory, Los Alamos, NM, USA. Keiken@lanl.gov
2. Low resistance to adefovir combined with Lamivudine: a 3-year study of 145 Lamivudine-resistant hepatitis B patients. Year Published: 2007
"A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy.
3. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Year Published: 2007
"A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy.
4. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.
5. Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. Year Published: 2007
Innogenetics N.V., Industriepark Zwijnaarde 7/4, B-9052 Ghent, Belgium. fred_shapiro@innogenetics.com.
6. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. Year Published: 2007
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, PR China.
7. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. Year Published: 2007
Innogenetics NV, Industriepark Zwijnaarde 7/4, B-9052, Ghent, Belgium.